Corvus Pharmaceuticals, Inc. Retained Earnings
Corvus Pharmaceuticals, Inc. (CRVS) had Retained Earnings of -$443.94 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$443.94M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$425.99M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$412.29M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$399.97M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$443.94M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$425.99M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$412.29M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$399.97M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$389.81M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$381.82M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$397.01M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$384.90M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$344.68M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$340.42M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$334.72M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$328.06M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$322.06M 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$315.56M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$307.69M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$297.87M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$283.04M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$274.68M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$266.38M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$257.14M 10-Q · filed 2021-11-01 |
| 2021-06-30 | -$246.47M 10-Q · filed 2021-08-02 |
| 2021-03-31 | -$234.72M 10-Q · filed 2021-04-29 |
| 2020-12-31 | -$223.14M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$250.49M 10-Q · filed 2020-10-29 |
| 2020-06-30 | -$240.69M 10-Q · filed 2020-07-30 |
| 2020-03-31 | -$230.08M 10-Q · filed 2020-04-30 |
| 2019-12-31 | -$217.15M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$206.10M 10-Q · filed 2019-10-29 |
| 2019-06-30 | -$195.09M 10-Q · filed 2019-08-01 |
| 2019-03-31 | -$182.12M 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$170.47M 10-K · filed 2020-03-09 |
| 2018-09-30 | -$159.96M 10-Q · filed 2018-11-01 |
| 2018-06-30 | -$149.47M 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$137.84M 10-Q · filed 2018-05-03 |
| 2017-12-31 | -$123.53M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$111.61M 10-Q · filed 2017-11-02 |
| 2017-06-30 | -$98.89M 10-Q · filed 2017-08-03 |
| 2017-03-31 | -$83.91M 10-Q · filed 2017-05-04 |
| 2016-12-31 | -$67.87M 10-K · filed 2018-03-01 |
| 2016-09-30 | -$56.78M 10-Q · filed 2016-11-03 |
| 2016-06-30 | -$46.49M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$37.84M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$31.50M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |